A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects with Relapsed Small Cell Lung Cancer After Platinum-based First-Line Chemotherapy (DeLLphi-304)

  • Markman, Ben (Primary Chief Investigator (PCI))
  • Brooks, Christine (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date25/06/23 → 24/06/25

Keywords

  • Clinical trial
  • DeLLphi-304